MedPath

Clinical Trial News

Pemivibart Guidelines Updated for COVID-19 Preexposure Prophylaxis in Immunocompromised Patients

  • The FDA authorized pemivibart for preexposure prophylaxis of COVID-19 in moderately to severely immunocompromised individuals aged 12 years and older.
  • IDSA updated its COVID-19 treatment guidelines, suggesting clinicians use pemivibart prophylactically when circulating variants are susceptible.
  • Pemivibart's efficacy is inferred via immunobridging, comparing it to adintrevimab, which showed reduced symptomatic COVID-19 risk in trials.
  • Emerging data suggest potential reduced susceptibility of pemivibart to newer variants, necessitating ongoing monitoring and research efforts.

A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2

NCT06039449CompletedPhase 3
Invivyd, Inc.
Posted 9/8/2023

Lenvatinib and Pembrolizumab Combination Shows Promise in Advanced Thymic Epithelial Tumors

  • The combination of lenvatinib and pembrolizumab demonstrated a promising 5-month progression-free survival (PFS) rate of nearly 90% in patients with platinum-refractory advanced thymic epithelial tumors.
  • Median PFS reached 14.9 months, with a 12-month PFS rate of 56%, indicating a potential new standard treatment for advanced B3-thymoma and thymic carcinoma.
  • The combination showed an objective response rate of 23.3% and manageable safety profile, though close monitoring for adverse events is crucial for optimal patient management.

Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents

NCT04710628Active, Not RecruitingPhase 2
MedSIR
Posted 9/21/2021

Comprehensive Digital System Reduces Symptom Burden in Cancer Patients Undergoing Chemotherapy

  • A randomized clinical trial evaluated the efficacy of a multicomponent digital intervention, Symptom Care at Home (SCH), in reducing symptom burden among cancer patients undergoing chemotherapy.
  • The complete SCH intervention, which includes automated self-management coaching and nurse practitioner (NP) follow-up with decision support, significantly reduced symptom burden compared to individual components alone.
  • NP follow-up was superior to self-management coaching, but there was no significant difference between activity tracker groups or between the two NP groups.
  • The study suggests that a comprehensive, multicomponent digital approach to cancer symptom management offers optimal symptom burden reduction and improved symptom control during chemotherapy.

SymptomCare@Home: Deconstructing an Effective Symptom Management Intervention

NCT02779725CompletedNot Applicable
University of Utah
Posted 8/7/2017

Fixed-Duration Venetoclax Regimens Offer CLL Patients a Balanced Approach

  • Fixed-duration treatments in CLL offer a defined treatment period, contrasting with continuous therapies that require ongoing administration until disease progression or unacceptable toxicity.
  • Venetoclax-based regimens, such as venetoclax plus obinutuzumab for 12 cycles in the frontline setting, provide a time-limited treatment option.
  • In the relapsed/refractory setting, venetoclax combined with rituximab is approved for 24 cycles, offering another fixed-duration approach for CLL management.

Real-World Study Uncovers Factors Influencing Long-Term Weight Loss with GLP-1 RAs

  • A Cleveland Clinic study identifies that the active agent, dosage, treatment indication, and persistence significantly impact long-term weight loss with GLP-1 RAs.
  • Semaglutide demonstrates a greater average weight reduction compared to liraglutide, with higher doses leading to more significant weight loss.
  • Patients treated for obesity showed better weight loss outcomes than those treated for type 2 diabetes, especially with consistent medication use.
  • Achieving at least 10% body weight reduction was more likely with semaglutide, higher doses, obesity treatment, and higher initial BMI.

VO659 Shows Promise in Reducing Mutant Huntingtin Protein in Huntington's Disease Patients

  • Interim Phase 1/2 data shows VO659, an antisense oligonucleotide, reduces mutant huntingtin protein (mHTT) in Huntington's disease patients.
  • Patients treated with 40mg of VO659 experienced a 28% mean reduction in mHTT in cerebrospinal fluid by day 85.
  • The treatment was generally safe and well-tolerated, with no significant changes in neurofilament light protein levels.
  • VO659's long half-life suggests potential for infrequent dosing, possibly once or twice per year, offering convenience.

A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD

NCT05822908RecruitingPhase 1
Vico Therapeutics B. V.
Posted 2/14/2023

Semaglutide Outperforms Liraglutide for Weight Loss in Real-World Study

  • Semaglutide (Ozempic, Wegovy) leads to ≥10% weight loss in 61% of obesity patients and 23% of diabetes patients, significantly higher than liraglutide (Saxenda).
  • Liraglutide achieved similar weight loss in only 29% of obesity patients and 12% of type 2 diabetes patients over one year.
  • The study highlights that higher doses of semaglutide and adherence to the drug schedule are associated with greater weight loss.
  • Findings emphasize the importance of medication persistence and patient-specific factors in achieving clinically significant weight reduction with GLP-1 receptor agonists.

AstraZeneca's Truqap (capivasertib) Launched in Korea as First AKT Inhibitor for Breast Cancer

  • AstraZeneca Korea has launched Truqap (capivasertib), the first AKT inhibitor approved in Korea, for HR-positive/HER2-negative breast cancer patients with specific mutations.
  • The approval was based on the CAPItello-291 trial, which showed a significant improvement in median progression-free survival when combined with fulvestrant.
  • Truqap targets PIK3CA, AKT1, or PTEN mutations, present in approximately 50% of HR-positive/HER2-negative breast cancer patients, addressing a critical need for effective second-line therapies.
  • Concerns remain regarding the financial burden on patients due to the high cost of next-generation sequencing (NGS) required to identify eligible patients.

Inhaled Colistimethate Shows Promise for Bronchiectasis, Despite COVID-19 Impact

  • In the PROMIS-I trial, inhaled colistimethate sodium significantly reduced the mean annual exacerbation rate in bronchiectasis patients with Pseudomonas aeruginosa infections.
  • The PROMIS-II trial, impacted by the COVID-19 pandemic, did not show a significant reduction in exacerbation rates with the same treatment.
  • A meta-analysis of PROMIS-I, pre-pandemic PROMIS-II data, and an earlier phase II study supported the efficacy of colistimethate sodium in reducing exacerbation rates.
  • Inhaled colistimethate sodium demonstrated a safety profile similar to placebo, with low rates of bronchospasm and manageable adverse events.

Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium.

NCT03460704TerminatedPhase 3
Zambon SpA
Posted 1/29/2018

Efficacy and Safety of Inhaled CMS in Bronchiectasis Subjects With Chronic P. Aeruginosa Infection. (PROMIS-I)

NCT03093974CompletedPhase 3
Zambon SpA
Posted 6/6/2017

Endo's Collagenase Clostridium Histolyticum Shows Promise in Phase 2 Plantar Fibromatosis Study

  • Endo presented Phase 2 clinical trial data of collagenase clostridium histolyticum (CCH) for plantar fibromatosis at the AOFAS annual meeting.
  • The study demonstrated a trend toward pain reduction with CCH treatment compared to placebo, as measured by the Foot Function Index.
  • CCH showed nominally significant improvements in investigator assessments of the condition, nodule hardness, and nodule consistency.
  • The safety profile of CCH in the study was consistent with previous findings, with mostly mild to moderate local adverse events reported.

Trending News

1

Lundbeck's Eptinezumab Shows Strong Efficacy in Asian Chronic Migraine Patients in Phase III SUNRISE Trial

2 days ago
2

Lilly's Once-Weekly Insulin Efsitora Alfa Achieves Non-Inferiority in Phase 3 Trials, Reducing Injection Burden by 300 Doses Annually

a day ago
3

Japanese Startup's Urine-Based Cancer Test Detects Stage 0 Lung Cancer in Hokkaido Pilot Study

2 days ago
4

Otsuka Pharmaceutical Secures Global Rights to HBM7020 BCMAxCD3 Bispecific T-Cell Engager for Autoimmune Diseases

20 hours ago
5

Novo Nordisk's Mim8 Shows Safe Direct Switch from Emicizumab in Phase 3b Hemophilia A Trial

a day ago
6

EMA Recommends Approval of Alvotech's Biosimilar to Eylea for Eye Disorders

12 hours ago
7

Roche's NXT007 Achieves Zero Bleeds in Phase I/II Hemophilia A Trial, Advances to Phase III

16 hours ago
8

XtalPi Secures $100 Million Partnership with Harvard's Gregory Verdine to Advance AI-Driven Drug Discovery

21 hours ago
9

Vertex and Ono Pharmaceutical Form Strategic Alliance for Povetacicept Development in Japan and South Korea

12 hours ago
10

Oryzon Submits Phase III Protocol for Vafidemstat in Borderline Personality Disorder, Targeting First FDA-Approved Treatment

9 hours ago
Subscribe Icon

Daily Pharma Insights

Get curated, high-impact pharmaceutical news delivered to your inbox every morning.

  • Critical clinical trial updates & results
  • Regulatory approvals & strategic partnerships
  • Market access decisions & commercial developments
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy